...
首页> 外文期刊>Journal of clinical lipidology >A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals
【24h】

A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals

机译:脂质学家对全球脂质指南和建议的看法,第2部分:脂质治疗目标

获取原文
获取原文并翻译 | 示例
           

摘要

Having knowledge of worldwide areas of harmonization and consensus regarding lipid guidelines and recommendations may provide clinicians a more global perspective on lipid management. This review examines 8 international scientific/medical organizations that have issued lipid guidelines, recommendations, and position papers: the National Lipid Association (2014), National Institute for Health and Care Excellence (2014), International Atherosclerosis Society (2013), American College of Cardiology/American Heart Association (2013), Canadian Cardiovascular Society (2013), Japan Atherosclerosis Society (2012), European Society of Cardiology/European Atherosclerosis Society (2012), and Adult Treatment Panel III (2001/2004). Part 1 of this perspective focused on sentinel components of these lipid guidelines and recommendations as applied to the role of atherogenic lipoprotein cholesterol levels, primary lipid target of therapy, other primary and secondary lipid treatment targets, and assessment of atherosclerotic cardiovascular disease (ASCVD) risk. This part 2 examines goals of lipid-altering therapy. While lipid guidelines and recommendations may differ regarding ASCVD risk assessment and lipid treatment goals, lipid guidelines and recommendations generally agree on the need to reduce atherogenic lipoprotein cholesterol levels, with statins being the first-line treatment of choice. (C) 2016 National Lipid Association. All rights reserved.
机译:了解全球范围内有关脂质指南和建议的协调一致和共识,可以为临床医生提供有关脂质管理的更全面的视角。这篇综述研究了8个发布了脂质指南,建议和立场文件的国际科学/医学组织:美国国家脂质协会(2014),美国国家健康与护理卓越研究所(2014),国际动脉粥样硬化学会(2013),美国大学医学院心脏病学/美国心脏协会(2013),加拿大心血管学会(2013),日本动脉粥样硬化学会(2012),欧洲心脏病学会/欧洲动脉粥样硬化学会(2012)和成人治疗小组III(2001/2004)。该观点的第1部分重点介绍了这些脂质指南和建议中的前哨成分,适用于致动脉粥样硬化性脂蛋白胆固醇水平的作用,治疗的主要脂质目标,其他主要和次要脂质治疗目标以及对动脉粥样硬化性心血管疾病(ASCVD)风险的评估。第2部分探讨了脂质改变疗法的目标。尽管关于ASCVD风险评估和脂质治疗目标的脂质指南和建议可能有所不同,但脂质指南和建议通常同意降低动脉粥样硬化性脂蛋白胆固醇水平的需要,他汀类药物是首选的一线治疗药物。 (C)2016年国家脂质协会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号